Detalimogene voraplasmid (EG-70)
Non-Muscle Invasive Bladder Cancer (NMIBC) - BCG-unresponsive
Phase 2/3Active (LEGEND Trial)
Key Facts
Indication
Non-Muscle Invasive Bladder Cancer (NMIBC) - BCG-unresponsive
Phase
Phase 2/3
Status
Active (LEGEND Trial)
Company
About enGene
enGene's mission is to mainstream genetic medicine by developing non-viral therapeutics delivered directly to mucosal tissues, starting with urological cancers. Its key achievement is advancing detalimogene into the pivotal LEGEND trial for NMIBC, supported by FDA RMAT and Fast Track designations. The company's strategy is to validate its proprietary DDX platform with this lead asset and subsequently expand its pipeline into other serious diseases affecting mucosal organs. enGene is publicly traded on NASDAQ, providing capital to execute its focused clinical and platform development plans.
View full company profile